Search - tctmd.com

Displaying 1 - 20 of 128

Sort: Relevancy | Date

Top News in Imaging: 2018

News Features

Top News in Imaging: 2018

December 28, 2018

Many PCI Patients Treated in China Have No Angina Symptoms

News Daily News

Many PCI Patients Treated in China Have No Angina Symptoms

December 20, 2018

Is It Time to Loosen Restrictions on Saturated Fats and Salt?

News Conference News WCC 2018

Is It Time to Loosen Restrictions on Saturated Fats and Salt?

December 14, 2018

Hospitals With Higher SAVR Mortality Likely to Have Higher TAVR Mortality, Too

News Daily News

Hospitals With Higher SAVR Mortality Likely to Have Higher TAVR Mortality, Too

December 12, 2018

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

News Daily News

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

December 07, 2018

True Resistant Hypertension Is Prevalent Worldwide

News Conference News WCC 2018

True Resistant Hypertension Is Prevalent Worldwide

December 07, 2018

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

News Daily News

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Michael O'Riordan

December 06, 2018

Complications Following TAVR Are Going Down, US Data Show

News Conference News AHA 2018

Complications Following TAVR Are Going Down, US Data Show

Yael L. Maxwell

November 20, 2018

Greater Need for Cooperative Care in Women’s Heart Health, Two Studies Suggest

News Conference News AHA 2018

Greater Need for Cooperative Care in Women’s Heart Health, Two Studies Suggest

Yael L. Maxwell

November 16, 2018

‘Accelerated Atherosclerosis’ Not Uncommon in Arteries of Young People

News Daily News

‘Accelerated Atherosclerosis’ Not Uncommon in Arteries of Young People

November 15, 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

November 15, 2018

News Conference News AHA 2018

Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI

Michael O'Riordan

November 14, 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

November 13, 2018

Cell Therapy No Help for Cardiac Recovery in HF Patients With LVADs

News Conference News AHA 2018

Cell Therapy No Help for Cardiac Recovery in HF Patients With LVADs

Yael L. Maxwell

November 12, 2018

New-Generation DES Better Than Older Stents Over 10 Years, Regardless of Polymer Type

News Conference News AHA 2018

New-Generation DES Better Than Older Stents Over 10 Years, Regardless of Polymer Type

November 12, 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

News Conference News AHA 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

November 11, 2018

Post-MI Yoga: Randomized Trial Shows Feasibility and Safety as an Option for Cardiac Rehab

News Conference News AHA 2018

Post-MI Yoga: Randomized Trial Shows Feasibility and Safety as an Option for Cardiac Rehab

Yael L. Maxwell

November 10, 2018

Lower Hypertension Range Tied to Heightened CVD Risk in Younger Adults

News Daily News

Lower Hypertension Range Tied to Heightened CVD Risk in Younger Adults

November 08, 2018

Race May Be a Proxy for Many Disparities in CVD Treatment, Outcomes

News Daily News

Race May Be a Proxy for Many Disparities in CVD Treatment, Outcomes

Yael L. Maxwell

November 07, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.